Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Investing.com - Brainstorm Cell Therapeutics reported on Monday third quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
Brainstorm Cell Therapeutics announced earnings per share of $-0.530 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.180 on revenue of $0.
Brainstorm Cell Therapeutics 's are down 45% and is trading at $1.760 , still down 62.55% from its 52 week high of $4.70 set on Monday, August 15, 2022.
Brainstorm Cell Therapeutics shares gained 15.79% to trade at $1.760 in intra-day trade the report.
Brainstorm Cell Therapeutics follows other major Healthcare sector earnings this month
Brainstorm Cell Therapeutics's report follows an earnings beat by J&J on Tuesday, October 18, 2022, who reported EPS of $2.55 on revenue of $23.79B, EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.98 on revenue of $6.94B, for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar